NovoCure Ltd — Director's Dealing 2020

Mar 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-03-03

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-03	Restricted Share Units	A	21623	—	Acquired	89344	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-03	Options to Buy Ordinary Shares	$69.37	A	41690	Acquired	2030-03-02	Ordinary Shares (41690.0)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.

F2: Options to buy 41,690 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.